Research and Reviews: Journal of Oncology and Hematology

Ewing’s Sarcoma (ES): A Single Centre Retrospective Study

  1. Aruna Kumari BS
  2. Lakshmaiah KC
  3. Appaji L
  4. Guruprasad Bhat ✉
  5. Samit Purohit
  6. Suresh TM
  7. Prasanna Kumari

Abstract

The treatment of Ewing’s sarcoma (ES), which is thought to be derived from primitive mesenchymal cells, involves chemotherapy, surgery and radiotherapy. While there is ample data in the world literature showing drastic changes in outcome of this disease, prognosis in Indian patients is largely unknown due to dearth of studies in our setting. The objective of the present study was to study the clinical, pathologic, cytogenetic profile and outcome of Ewing’s sarcoma (ES) with combined modality of treatment. Fifty six patients who had pathologically proven diagnosis of Ewing’s sarcoma and had received treatment at our institute from 2003 to 2008 were included for retrospective analysis. These patients were treated as per first POG-CCG protocol and subjected to surgery, radiotherapy and chemotherapy and the outcome (event-free survival, local and systemic relapses, disease progression) was noted. These outcomes were correlated with site, volume of tumor, stage at presentation, patient age and cytogenetics. The results revealed that at a median follow-up of 36 months (range 6–86 months) the median event free survival was 24 months (m) while the 5-year event free survival rate was 36 ± 4.6%. High tumor volume, pelvic disease and metastasis at presentation had poor outcome. There was no correlation between age and cytogenetics with survival. Although the demographic profile in our study was similar to the world literature, the outcome of Ewing’s sarcoma in Indian patients was found to be inferior, with localised disease having an approximately fifty percent chance of being cured and a much worse outcome in the setting of pelvic disease, high tumor burden and metastasis at presentation.Keywords: Ewing’s Sarcoma (ES), Paediatric Oncology Group–Children's Cancer Group (POG-CCG), Cytogenetic

References (15)

  1. Iyer RS, Rao SR, Gur jal A, et al. Ewing’s sarcoma. J. Surg. Oncol. 1993. 52. 188–92p.
  2. Grier HE , Krailo MD , Tarbell NJ , et al. Addition of ifosfamide and etoposide to standard chemotherapy fo r Ewing's sarcoma and primitive neuroectodermal tumor of bone. N. Engl. J. Med. 2003; 348: 694–701p.
  3. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J. Clin. Oncol. 2000; 18: 3108–14p.
  4. Cangir A, Vietti TJ, Gehan EA, et al. Ewing’s sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing’s sarcoma studies. Cancer. 1990 ; 66: 887–893p.
  5. Rodríguez-Galindo C, Liu T, Krasin MJ, et al. Analysis of prognostic factors in Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer. 2007; 110: 375–84p.
  6. Obata H, Ueda T, Kawai A, Ishii T, Ozaki T, Abe S, et al. Japanese Musculoskeletal Oncology Group. Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study. Cancer. 2007; 109: 767–75p.
  7. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res. 2007; 459: 40–47p.
  8. Lee J, Hoang BH, Ziogas A, Zell J A. Analysis of progno stic factors in Ewing sarcoma using a population -based cancer registry. Cancer. 2010: 116: 1964–73p.
  9. Avigad S, Cohen IJ, Ziberstein J, et al. The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors. Cancer. 2004; 100: 1053–8p.
  10. De Alava E, Kawai A, Healey JH, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing’s sarcoma. J Clin Oncol . 1998; 16: 1248–55p.
  11. Zoubek A, Dockhorn -Dworniczak B, Delattre O, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J. Clin. Oncol. 1996; 14: 1245–1251p.
  12. Kullendorff CM, Mertens F, Donnér M, et al., Cytogenetic aberrations in Ewing sarcoma: are secondary changes associated with clinical outcome? Med Pediatr Oncol. 1999; 32: 79–83p.
  13. Udayakumar AM, Sundareshan T S, Goud TM, et al. Cytogenetic characterization of Ewing tumors using fine needle aspiration sample: a 10 -year experience and review Research & Reviews: Journal of Oncology and Haematology Volume 2, Issue 2, ISSN 2319 – 3387 __________________________________________________________________________________________ RRJoOH(2013) 1-7 © STM Journals 2013. All Rights Reserved Page 7 of the literature. Cancer Genet Cy togenet. 2001; 127: 42–8p.
  14. Le Deley MC, Delattre O, Schaefer KL, et al. Impact of EWS -ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitiv e neuroectodermal tumor: prospective results from the cooperative Euro - E.W.I.N.G. 99 trial . J Clin Oncol. 2010; 28: 1982–8p.
  15. Baldini EH, Demetri GD, Fletcher CD, et al. Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome Ann Surg. 1999; 230: 79–86p.

Read more of it

Subscribe to one journal or build your own list of several. One invoice, one payment, access for a full year.

Subscribe to journals →

Publish your article

Peer-reviewed journals across every subject, with open access options. Send your manuscript to the right editor today.

Publish with us → Calculate your APC
Support